» Articles » PMID: 20350917

Effect of Dexamethasone on Oral Glucose Tolerance in Healthy Adults

Overview
Journal Endocr Pract
Specialty Endocrinology
Date 2010 Mar 31
PMID 20350917
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To determine the dose-response and time course of action of a single dose of dexamethasone on plasma glucose and insulin dynamics in healthy adults.

Methods: Participants included healthy adults who met the following inclusion criteria: 18 to 65 years of age, body mass index of 18 to 25 kg/m2, no family history of diabetes mellitus, not taking any medication known to affect glucose tolerance, and nonpregnant state for female participants. Each participant underwent 3 sequential blocks of 75-g oral glucose tolerance tests (OGTTs) on days 1, 2, and 3; this sequence was repeated on 3 different occasions separated by more than 2 weeks. On the first day of each block, participants reported to the research center after a 10- to 12-hour overnight fast, and fasting baseline blood samples for glucose, insulin, and C-peptide were obtained. Baseline (0 mg) OGTT was then performed with a 75-g glucose load, and blood samples were collected at 30, 60, 90, and 120 minutes for measurements of glucose, insulin, and C-peptide. After the baseline OGTT on day 1, a single dose of either 2-, 4- or 8-mg of dexamethasone was administered orally. Twenty-four and 48 hours later, participants returned for additional OGTTs.

Results: Ten healthy volunteers (4 male and 6 female) were enrolled. The effect of dexamethasone was maximal 24 hours after 8-mg dexamethasone compared with the effect observed after no dexamethasone administration. At 60 minutes during the OGTT (following 8-mg dexamethasone), blood glucose increased from 127 ± 7.1 mg/dL (6.35 ± 0.36 mmol/L) to 176 ± 19 mg/dL (8.8 ± 0.95 mmol/L), insulin increased from 49.3 ± 3.2 μIU/mL (342 ± 22 pmol/L) to 119.7 ± 10.1 μIU/mL (831 ± 70 pmol/L), and C-peptide increased from 6376 ± 510 pg/L (1913 ± 153 pmol/L) to 10 143 ± 1016 pg/L (3043 ± 305 pmol/L); the 60-minute levels returned towards baseline at 48 hours. Smaller changes were observed with 2- and 4-mg dexamethasone. Twenty-four hours after 8-mg dexamethasone, there was a 2.2- and 1.5-fold increase in homeostasis model assessment of insulin resistance and homeostasis model assessment of β cells, respectively, and a 2.5-fold decrease in the Matsuda sensitivity index.

Conclusions: A single oral dose of 8-mg dexamethasone increases blood glucose, insulin, and C-peptide levels maximally at 24 hours, 1 hour following 75-g OGTT. A dexamethasone stress test might identify persons at increased risk for type 2 diabetes.

Citing Articles

Submucosal Infiltration versus Intravenous Administration of Dexamethasone in Decreasing Post-operative Inflammatory Sequelae after Third Molar Surgery - A Comparative Study.

Naik V, Shankar M, Agarwal R, Rai K, Karande A, Humne A Ann Maxillofac Surg. 2025; 14(2):141-146.

PMID: 39957872 PMC: 11828056. DOI: 10.4103/ams.ams_35_24.


Long-term outcome of patients with diabetic-range hyperglycemia first detected during admission for COVID-19: A single-center observational study.

Agarwal K, Kirti R, Shyama S, Kumar P, Biswas R, Ojha V J Family Med Prim Care. 2024; 13(8):3374-3380.

PMID: 39228533 PMC: 11368375. DOI: 10.4103/jfmpc.jfmpc_140_24.


Drug-induced Steatohepatitis Caused by Long-term Use of Topical Steroids for Atopic Dermatitis.

Tamura Y, Naganuma A, Suzuki Y, Uehara S, Hoshino T, Hatanaka T Intern Med. 2024; 63(23):3165-3170.

PMID: 38599864 PMC: 11671201. DOI: 10.2169/internalmedicine.3439-23.


Type 2 Diabetes Polygenic Score Predicts the Risk of Glucocorticoid-Induced Hyperglycemia in Patients Without Diabetes.

Deutsch A, Schroeder P, Mandla R, Kang S, Erenler F, Mercader J Diabetes Care. 2023; 46(8):1541-1545.

PMID: 37353344 PMC: 10369128. DOI: 10.2337/dc23-0353.


No effect of the turmeric root phenol curcumin on prednisolone-induced glucometabolic perturbations in men with overweight or obesity.

Hellmann P, Bagger J, Carlander K, Hansen K, Forman J, Storling J Endocr Connect. 2023; 12(4).

PMID: 36800259 PMC: 10083679. DOI: 10.1530/EC-22-0334.